Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The company is a leader in the international development and commercialization of medicines for infectious diseases and oncology.

Gilead Sciences maintains research, development or manufacturing facilities in three locations in the United States and two locations in Europe. In the United States, operations are based in Foster City, California (corporate headquarters); San Dimas, California and Boulder, Colorado. European operations are based in Cambridge, UK and Dublin, Ireland. Additionally, sales and marketing organizations are located in the following cities: Athens, Greece; Cambridge, UK; Lisbon, Portugal; Madrid, Spain; Melbourne, Australia; Milan, Italy; Munich, Germany; Paris, France and Vienna, Austria.

Between 1988 and 1989, Gilead Sciences raised $12 million in venture capital and established its current headquarters in Foster City, California. In 1992, Gilead completed its initial public offering, raising $86.25 million, and submitted its first Investigational New Drug Application to the U.S. Food and Drug Administration (FDA) for Vistide® (cidofovir injection). Vistide, a treatment for cytomegalovirus (CMV) retinitis in patients with AIDS, was approved in 1996 by the FDA and in 1997 by the European Medicines Evaluation Agency. From 1996 through the present, Gilead has made extensive progress in the development of unique products for the potential treatment of a wide range of viral diseases, including HIV, hepatitis B virus infection and influenza.

In July 1999, the acquisition of NeXstar Pharmaceuticals, Inc. solidified Gilead's commitment to becoming a worldwide leader in the pharmaceutical industry. A transforming event, the merger expanded Gilead's ability to implement this business philosophy by fortifying key areas within the organization. The Company also significantly increased its portfolio of commercial and investigational products and enhanced the technologies employed by its scientists to discover and develop new therapeutic agents.

With approximately 750 employees worldwide, Gilead employs 470 individuals in research and development functions, 160 in sales and marketing and 130 in general and administrative positions.

To compete in broader markets that require significant development or extensive sales organizations, Gilead relies on large commercial partners. Gilead has built a network of important external alliances to leverage its clinical development and commercialization efforts.

The Gilead product portfolio includes four approved products and four investigational products in clinical development. In addition, Gilead's sales force provides promotional support for Virco's phenotypic and genotypic HIV resistance testing services.

Products on the Market

AmBisome® (amphotericin B) liposome for injection is a treatment for life-threatening, systemic fungal infections. AmBisome is the first and only amphotericin B product approved for use in the United States by the FDA for empiric therapy for presumed fungal infections in patients with low blood cell counts and who exhibit fever of unknown origin. AmBisome is available in 41 countries.

TamifluT (oseltamivir phosphate) is the first oral neuraminidase inhibitor for the treatment of influenza A and B in adults. Developed in partnership between Gilead and Roche, Tamiflu received FDA approval in October 1999 and is also available in Argentina, Brazil, Canada, Chile, Mexico, New Zealand, Peru, Switzerland and Uruguay. Roche is conducting a series of ongoing studies to expand the indications and availability of Tamiflu worldwide.

DaunoXome® (daunorubicin citrate liposome injection) is a liposomal form of the anticancer agent daunorubicin, and is indicated for first-line therapy of patients with advanced AIDS-related Kaposi's sarcoma (KS). DaunoXome is the only oncology product to receive clearance as a first-line chemotherapy agent for treatment of KS in the United States. DaunoXome is available in 34 countries worldwide.

Vistide® (cidofovir injection) is an antiviral for the treatment of CMV retinitis in patients with AIDS.

AntivirogramT Phenotypic Resistance Testing, VircoGENT Genotypic Resistance Testing and VirtualPhenotypeT Genotypic Interpretation, Virco's portfolio of phenotypic and genotypic services, are marketed by the Gilead sales force to AIDS-treating physicians in the United States.

Investigational Products

Infectious Diseases

Tenofovir Disoproxil Fumarate (tenofovir DF), an investigational, once-daily, orally-administered nucleotide reverse transcriptase inhibitor for the potential treatment of HIV, is currently in Phase III clinical trials in the United States, South America, Europe and Australia.

Adefovir Dipivoxil an investigational once-daily, orally-administered nucleotide for the potential treatment of chronic hepatitis B virus infection, is currently in Phase III clinical trials in the United States, Canada, Europe, Australia and Southeast Asia.

Oncology

DaunoXome currently indicated as a chemotherapy agent for the treatment of advanced AIDS-related KS, is in Phase II clinical trials for evaluation as a potential treatment for acute myelogenous leukemia.

NX 211 (liposomal lurtotecan), a liposomal formulation of the anti-cancer agent lurtotecan, is in Phase I clinical testing for the potential treatment of a variety of solid tumors.

In addition to these products in clinical development, Gilead maintains an active, multi-disciplinary research program, which draws on individuals across the organization with a wide range of skills in many different areas of science and medicine.

Areas of preclinical development include HIV protease inhibitors, oncology and small molecule antibacterials. Gilead is also exploring the development of adenosine receptor regulators, which may play an important role in treating and preventing neurodegenerative disorders.

Gilead's research is dedicated to the discovery of potent and selective drugs in the therapeutic areas of infectious diseases and cancer. The Company's research seeks to address important issues within these treatment areas, such as the emergence of resistance to currently available antiretroviral and antibacterial therapies and selective targeting to diseased tissue.